{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T05:39:28Z","timestamp":1777354768146,"version":"3.51.4"},"reference-count":16,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,1,30]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the immunogenicity of pneumococcal 13-valent conjugate vaccination (PCV-13) in patients with rheumatoid arthritis receiving upadacitinib and background methotrexate (MTX).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eligible patients from the phase 2 open-label extension trial BALANCE-EXTEND (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02049138\">NCT02049138<\/jats:ext-link>) receiving stable dosing of upadacitinib 15\u2009mg or 30\u2009mg once daily plus background MTX were given PCV-13. Antibody titres were collected prevaccination and 4 and 12 weeks postvaccination. The primary endpoint was the proportion of patients with satisfactory humoral response to PCV-13, defined as a \u22652-fold increase in \u22656 of 12 pneumococcal antigens at 4 weeks postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 111 patients (upadacitinib 15\u2009mg, N=87; 30\u2009mg, N=24), 85.6% were women, 97.3% used concomitant MTX and 44.1% used oral corticosteroids. At 4 weeks, 67.5% (95% CI 57.4 to 77.5) of patients receiving upadacitinib 15\u2009mg and 56.5% (36.3 to 76.8) receiving 30\u2009mg had a satisfactory PCV-13 response. Responses were similar in patients who used or did not use concomitant corticosteroids. No deaths or serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Approximately two-thirds of patients receiving upadacitinib 15\u2009mg once daily achieved a satisfactory humoral response to PCV-13 despite receiving concomitant MTX. Concomitant corticosteroid use did not negatively affect PCV-13 response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-002110","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T11:13:56Z","timestamp":1646392436000},"page":"e002110","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02049138","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02049138","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-6947","authenticated-orcid":false,"given":"Kevin","family":"Winthrop","sequence":"first","affiliation":[{"name":"Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ignacio","family":"Vargas","sequence":"additional","affiliation":[{"name":"Medicine, Quantum Research, Puerto Varas, Los Lagos, Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edit","family":"Drescher","sequence":"additional","affiliation":[{"name":"Rheumatology, Veszpr\u00e9m Csolnoky Ferenc County Hospital, Veszpr\u00e9m, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrado","family":"Garcia","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Hospital General de M\u00e9xico Dr Eduardo Liceaga, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Friedman","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Hendrickson","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihan","family":"Li","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Klaff","sequence":"additional","affiliation":[{"name":"Immunology, AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Kivitz","sequence":"additional","affiliation":[{"name":"Altoona Center for Clinical Research, Duncansville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"2025090313542485000_8.1.e002110.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes305"},{"key":"2025090313542485000_8.1.e002110.2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a010215"},{"key":"2025090313542485000_8.1.e002110.3","first-page":"1","article-title":"American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"2016","author":"Singh","year":"2015","journal-title":"Arthritis Care Res"},{"key":"2025090313542485000_8.1.e002110.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204427"},{"key":"2025090313542485000_8.1.e002110.5","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0019-6","article-title":"Antibody response to 13-valent pneumococcal conjugate vaccine is not impaired in patients with rheumatoid arthritis or primary Sj\u00f6gren's syndrome without disease modifying treatment","volume":"2","author":"Nived","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090313542485000_8.1.e002110.6","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1883-1"},{"key":"2025090313542485000_8.1.e002110.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-207191"},{"key":"2025090313542485000_8.1.e002110.8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"2025090313542485000_8.1.e002110.9","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/art.39801","article-title":"A phase IIb study of ABT-494, a selective JAK-1 inhibitor, in patients with rheumatoid arthritis and an inadequate response to anti-tumor necrosis factor therapy","volume":"68","author":"Kremer","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313542485000_8.1.e002110.10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/art.39808","article-title":"Efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in a phase IIb study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090313542485000_8.1.e002110.11","unstructured":"U.S. Food Drug and Administration . Prevnar 13 prescribing information, 2017. Available: https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert-Prevnar-13.pdf [Accessed 23 Jun 2021]."},{"key":"2025090313542485000_8.1.e002110.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.07.002"},{"key":"2025090313542485000_8.1.e002110.13","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00735-14"},{"key":"2025090313542485000_8.1.e002110.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.068"},{"key":"2025090313542485000_8.1.e002110.15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009742.2020.1732459","article-title":"Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status","volume":"49","author":"Rasmussen","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"2025090313542485000_8.1.e002110.16","unstructured":"CDC . Recommended adult immunization schedule, 2021. Available: https:\/\/www.cdc.gov\/vaccines\/schedules\/downloads\/adult\/adult-combined-schedule.pdf [Accessed 27 Jun 2021]."}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-002110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:54:35Z","timestamp":1756932875000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-002110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,4]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/rmdopen-2021-002110"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-002110","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}